新药周观点：创新药3月进院数据更新，多个新纳入医保创新药快速进院中-20250525

Investment Rating - The report maintains an investment rating of "Outperform-A" for the biopharmaceutical sector [7] Core Insights - The report highlights that several newly included innovative drugs in the medical insurance directory are rapidly entering hospitals, with significant growth in hospital admissions for specific drugs compared to the end of December 2024 [2][20] - The report notes that the new drug market has seen substantial fluctuations, with the top five gainers and losers in the new drug sector during the week of May 19 to May 23, 2025 [1][16] Summary by Sections New Drug Market Review - From May 19 to May 23, 2025, the top five companies in the new drug sector by stock price increase were: - Sanofi (99.96%) - Oconovision Biotech-B (43.66%) - Yiming Oncology-B (38.40%) - Chuangsheng Group-B (36.45%) - Canaan Jiangrui Pharmaceutical-B (34.03%) - The top five companies by stock price decrease were: - Junsheng Tai Pharmaceutical-B (-14.33%) - Mengke Pharmaceutical (-3.34%) - Dize Pharmaceutical (-2.88%) - Yunding Xinyao (-2.70%) - Dongyao Pharmaceutical-B (-2.66%) [1][16] Key Industry Analysis - The National Medical Insurance Administration updated the hospital admission data for innovative drugs included in the medical insurance directory as of the end of March 2025, showing rapid hospital entry for several newly included domestic innovative drugs [2][20] - Notable drugs with fast growth in hospital admissions include: - Yunding Xinyao's Budesonide Enteric-Coated Capsules - Zaiqian Pharmaceutical's Recombinant Human Thrombin - Innovent Biologics' Toripalimab - Haisco's Alogliptin and Clobazam - Xinlitai's Aliskiren Amlodipine and Benzyl Glimepiride - Hengrui Medicine's Otilonium Bromide - China National Pharmaceutical's Anakinra and Ivosidenib [2][20][21] New Drug Approval and Acceptance - This week, 10 new drugs or new indications received approval for market entry, including: - Pyrocyclic Tablets by Xuan Bamboo Biotechnology - Anlotinib Hydrochloride Capsules by Zhengda Tianqing - Injection of Camrelizumab by Shengdiya Biopharmaceutical - Injection of Bemarituzumab by Zhengda Tianqing - Injection of Vilazodone by Beihai Kangcheng - Injection of Acetylcysteine by Jingding Pharmaceutical - Ribociclib Succinate Tablets by Novartis - Asunaprevir Tablets by Novartis - Injection of Tenecteplase by Boehringer Ingelheim - Injection of Tanshinone by Novartis [3][24] Clinical Application Approval and Acceptance - This week, 10 new drug clinical applications were approved, and 43 new drug clinical applications were accepted [4][29]